FibroBiologics, Inc. Common StockFBLGNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+53.6%
5Y CAGR+69.1%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+53.6%/yr
Annual compound
5Y CAGR
+69.1%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
13.8x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$16.18M+17.8%
2024$13.74M+54.5%
2023$8.89M+99.0%
2022$4.47M+183.1%
2021$1.58M+35.0%
2020$1.17M-